Back to catalogue
№ 276 15 filings · 2024-12-11 → 2026-08-21

OPTIMA HEALTH PLC

OPT
Health Care Share price 244p Market cap £265m Overall fit 260 /1000

Fair-priced quality UK healthcare roll-up with credible growth, but essentially no AI-receiver angle, only moderate operating leverage, and stretched balance sheet — the antithesis of what this strategy is looking for despite being a decent business in its own right.

Fair value range 200p–250p Mid case · £245m
Absolute upside -7.7% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Recent pro-forma disclosures for enlarged group provide a workable EBITDA anchor
  • Peer EV/EBITDA framework well-established for UK health services roll-ups
  • Management has met or modestly beaten guidance in every period since AIM listing
Limits the call
  • Only two years of public financials post-demerger; PAM synergies unaudited
  • Interim CFO appointment mid-integration adds execution uncertainty
Methodology

Blended EV/EBITDA on FY27E pro-forma and discounted medium-term target

In one line · bull case

UK #1 in a structurally growing occupational-health market with credible path to £40m EBITDA — but priced roughly at fair value and offering little of the AI-receiver / high-operating-leverage profile the strategy targets.

In one line · biggest risk

PAM integration slippage combined with 2.7x leverage and a mid-integration CFO change could turn a fair-priced quality name into a covenant-stressed disappointment.

Drivers
AI beneficiary 15 /100
Labour-intensive clinician services group that spends on AI feasibility; DART digital tool is trivial in mix and Optima is not in the AI value chain.
Operating leverage 40 /100
Clinician cost dominates and scales with revenue; central and platform costs are fixed but modest; margin path to 20% relies on execution not natural leverage.
Earnings vs expectations 62 /100
10% FY26 EBITDA beat vs. £18.1m consensus; prior updates in line; no misses since Sep-2024 listing.
Growth momentum 72 /100
15-17% top-line growth; PAM lifts scale sharply; £210m Armed Forces contract mobilising into FY27.
Moat 38 /100
Scale, national clinic footprint, and multi-year public-sector contracts provide moderate defensibility in a fragmented market.
Earnings quality 45 /100
Large amortisation of acquisition intangibles and repeated exceptional items keep statutory PBT well below adjusted; £4.7m one-off DWP settlement flatters FY26.
Management quality 55 /100
Consistent strategic execution and disciplined M&A, but unexplained CFO change and related-party financing from largest shareholder are watch-items.
Cyclicality 22 /100
Occupational health is statutory-driven and highly defensive; resilient through economic cycles.
Leverage 58 /100
Pro-forma net debt/EBITDA 2.7x post-PAM; targeted <1x by year 3; related-party bridge governance concern.
Value-trap signals · 4
  • Related-party bridge and open-offer underwriting from major shareholder Lord Ashcroft with £2.5m fee
  • Large persistent gap between statutory profit and adjusted EBITDA driven by heavy acquisition-intangible amortisation
  • Unexplained CFO change immediately before FY26 results and during PAM integration
  • FY26 EBITDA beat partly flattered by £4.7m non-recurring DWP settlement

OPTIMA HEALTH PLC (OPT) — Investment Research Note

Executive summary

Optima Health is the UK & Ireland's largest occupational-health services group, delivering clinician-led health assessments, wellbeing programmes, and mental-health/EAP services under long-term B2B contracts to public and private employers. Since demerging from Marlowe plc and listing on AIM in September 2024, the group has grown revenue from £105m (FY25) to c.£121m (FY26, +15%), completed five acquisitions culminating in the £100m PAM Healthcare deal (March 2026), and moved medium-term targets of £200m revenue and £40m adjusted EBITDA within reach. The single most important valuation point today is that current pricing (238p, £259m mcap) already reflects the PAM synergies but the shares are unproven at proforma leverage of 2.7x and the AI angle is essentially absent.

Fair value estimate

Methodology: blended EV/EBITDA multiple applied to (i) FY27 pro-forma adjusted EBITDA and (ii) discounted medium-term target EBITDA.

Key inputs (all GBP):

  • FY26A adj EBITDA c.£20m (10% ahead of £18.1m consensus 2026-04-17 trading update)
  • Pro-forma combined adj EBITDA >£26m before synergies 2026-02-16 PAM acquisition
  • Announced synergies £5m p.a. by year 3, £1.5m in year 1, £1.3m annualised already delivered by June 2026 2026-06-16 trading update
  • FY27E adj EBITDA £29-32m (full-year PAM + partial synergies + organic growth)
  • Post-open-offer net debt c.£64m (after £30m bridge repayment); leases add ~£6-8m
  • Shares outstanding 108.8m (post open offer at 175p)

Multiples: UK healthcare-services / testing peers (e.g. Craneware, Ergomed history, RWS-style analogues) trade 8-11x EV/EBITDA at similar leverage. Applying 9-11x to £30m FY27E EBITDA:

  • EV range: £270m – £330m
  • Less net debt £64m → equity £206m – £266m
  • Per share: 189p – 244p

A discounted medium-term case (£40m EBITDA × 9x = £360m EV, less £30m residual debt after deleveraging, discounted 2yr @10%) gives ~250p.

Fair value range: 200p – 250p; mid ~225p; implied mcap £217m – £272m (mid £245m).

vs. current 238p / £259m mcap → absolute downside ~5% to mid, range −16% to +5%. View: fair (marginally full).

Sector context

  • ICB Health Care confirmed; sub-sector is B2B occupational-health services (clinician-delivered, contract-based, low capital intensity).
  • Quality/growth/leverage profile: growth (15% top-line) is above sector norm; margins (adj EBITDA ~13-17%, targeting 20%) are in line with health-services peers; leverage (2.7x proforma) is above sector norm following PAM.
  • Listed peers: Craneware (health-tech SaaS, higher-quality analogue); CVS Group (roll-up services, similar M&A playbook); Diaceutics / Ergomed (asset-light health services). No clean pure-play OH comparable in London.

Investment thesis

  • Structural market tailwind + consolidation runway. UK/Ireland OH market £1.6bn growing 9% p.a.; only 45% UK workforce covered vs. 80%+ in peer Europe; market highly fragmented with Optima now #1 at 15% proforma share targeting 25% 2026-02-16 PAM acquisition. Statutory drivers (Health & Safety at Work Act) make demand non-discretionary.
  • PAM acquisition is materially accretive. >25% adj EPS accretion by year 3, £5m synergies (of which £1.3m already delivered by June 2026), and combined pro-forma adj EBITDA >£26m pre-synergies against £258.9m mcap 2026-02-16 acquisition; 2026-06-16 trading update.
  • Contract backlog underpins revenue visibility. £210m UK Armed Forces medical assessment contract (with Serco) mobilising from H1 FY27 adding £20m+ p.a.; >90% of PAM's FY26 revenues underpinned by existing contracts; DART digital-triage tool now live in five NHS trusts opening a new licensing revenue line 2025-07-08 FY25 results; 2025-12-10 interim results.

Key risks

  • Leverage and related-party governance. Pro-forma net debt 2.7x EBITDA; £30m bridge financed by Lord Ashcroft's Deacon Street with a £2.5m fee, underwriting the Open Offer at 175p (17.8% discount), with structure that could take him through 30% requiring a Rule 9 waiver 2026-02-16 PAM. Any integration slippage would test covenants (3.5x → 3.0x tightening) and increase minority-shareholder dilution risk.
  • Margin compression is real and ongoing. Adj EBITDA margin fell 320bps H1-to-H1 (17.1% → 13.9%) on NI hike, listing costs, and clinician wage inflation; the transformation programme won't deliver until H2 FY27 2025-12-10 interim results. Route to the 20% medium-term margin is credible but not yet earned.
  • CFO departure. Heidi Giles (CFO through FY25/FY26 process) has been replaced by Interim CFO Andrew Bones just ahead of PAM full-year results — no explanation given in the 21 August 2026 AGM notice; a red flag inside a leveraged integration period 2026-08-21 AGM notice vs. 2026-06-16 trading update.

Operating leverage

Optima's cost base is dominated by clinician salaries (>1,250 direct clinicians plus 1,000 subcontracted associates), which scale broadly with revenue — gross margin has actually compressed slightly as new business is added (H1 FY26 gross margin 26.4% vs. FY25 31.5%). Fixed costs sit in central plc functions, IT platform (proprietary systems, DART), and c.50 clinic footprint. Adjusted EBITDA margin trajectory has been 16.7% (FY25) → 13.9% (H1 FY26) → recovering to c.16-17% FY26 as PAM contribution and synergies land; the medium-term 20% target implies £8-10m of margin uplift from a mix of central-cost leverage, clinician-productivity software, and site-rationalisation synergies. This is moderate operating leverage, not the high-fixed-cost software profile the strategy prefers. A 10-20% revenue beat above the £200m plan would plausibly add 30-50% to operating profit given the fixed central cost base, but not the "multiples of profit" outcome specified in the mandate. The DART SaaS layer is optionality but immaterial today.

Value-trap signals

  • Related-party bridge financing from largest shareholder (Lord Ashcroft) with a £2.5m fee attached.
  • Wide and persistent gap between statutory and adjusted profit (FY25 statutory PBT £2.6m vs. adjusted £12.8m); £6-8m p.a. of acquisition-intangible amortisation running through P&L.
  • Unexplained CFO change mid-way through PAM integration.
  • Customer concentration modest — one customer >10% of revenue (~14%).

Earnings vs. expectations

  • HY26 (Dec 2025): revenue £59.5m "in line with market expectations"; adj EBITDA £8.3m below prior year (£8.7m) on NI hike — in line.
  • Q3 FY26 update (April 2026): adj EBITDA now expected c.10% ahead of £18.1m consensus → beat.
  • FY26 trading update (June 2026): revenue £121m in line; adj EBITDA reaffirmed 10% ahead → beat.
  • FY25 (July 2025): revenue £105m and adj EBITDA £17.6m "in line with market expectations at the time of the Company's listing" → met.

Pattern: since listing, Optima has delivered either "in line" or modest beats — no misses. The FY26 EBITDA beat came late in the year and was helped by £4.7m of one-off other income from a DWP legal settlement, which is real cash but non-recurring.

Conviction: 3 (moderate)

Anchoring my view: (i) recent, well-disclosed pro-forma financials for the enlarged group with PAM; (ii) clear peer-multiple framework applicable to health services; (iii) consistent management execution on both organic growth and stated M&A pipeline. Limiting my view: (i) short public-market history (only two full sets of results since Sep-2024 listing) makes trend extrapolation weak; (ii) integration risk on PAM is real and synergy delivery is unaudited; (iii) CFO change adds noise.

Driver scoring rationale (see JSON)

Weakest fit for this mandate is AI-beneficiary — Optima is a labour-intensive services roll-up that "spends" on AI feasibility studies, not a picks-and-shovels AI receiver. Operating leverage is moderate not high. Valuation is fair not cheap. Balance sheet is stretched by PAM. Overall score modest.

Filings consulted · 15

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-08-21Notice OF Agm And Posting OF Annual Report2026-08-21_9733069_notice-of-agm-and-posting-of-annual-report.md0.95
  2. 2026-08-10Notice OF Full Year Results2026-08-10_9711935_notice-of-full-year-results.md1.00
  3. 2026-06-16Full Year Trading Update2026-06-16_9619503_full-year-trading-update.md0.85
  4. 2026-04-17Full Year Trading Update2026-04-17_9524825_full-year-trading-update.md0.85
  5. 2026-03-24Irish Fdi Clearance Amp Expected Acquisition OF Pam2026-03-24_9490025_irish-fdi-clearance-amp-expected-acquisition-of-pam.md0.75
  6. 2026-02-16Acquisition OF Pam Healthcare Limited2026-02-16_9431337_acquisition-of-pam-healthcare-limited.md0.64
  7. 2025-12-10Interim Results2025-12-10_9286446_interim-results.md0.77
  8. 2025-11-13Notice OF Half Year Results2025-11-13_9230297_notice-of-half-year-results.md0.77
  9. 2025-11-03Half Year Trading Update2025-11-03_9207461_half-year-trading-update.md0.77
  10. 2025-09-01Result OF Agm2025-09-01_9083349_result-of-agm.md0.26
  11. 2025-07-30Notice OF Agm And Posting OF Annual Report2025-07-30_9011391_notice-of-agm-and-posting-of-annual-report.md0.62
  12. 2025-07-08Full Year Results2025-07-08_8967607_full-year-results.md0.65
  13. 2025-06-05Notice OF Full Year Results2025-06-05_8913755_notice-of-full-year-results.md0.65
  14. 2025-05-12Full Year Trading Update2025-05-12_8871465_full-year-trading-update.md0.55
  15. 2024-12-11Interim Results2024-12-11_8603094_interim-results.md0.58

This research note was authored by a large language model after reading 15 regulatory filings published between 2024-12-11 and 2026-08-21. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.